Trial Profile

A Phase 1/2 Study of LY3499446 Administered to Patients With Advanced Solid Tumors With KRAS G12C Mutation

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Cetuximab (Primary) ; Erlotinib (Primary) ; LY 3499446 (Primary) ; Docetaxel
Indications Colorectal cancer; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

07 Dec 2020 Status changed from active, no longer recruiting to discontinued due to an unexpected toxicity finding.
03 Aug 2020 Status changed from recruiting to active, no longer recruiting.
17 Jul 2020 Status changed from suspended to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com